HeraMED Limited
HeraMED Limited (HMD.AX) Financial Performance & Income Statement Overview
Analyze HeraMED Limited (HMD.AX) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
HeraMED Limited (HMD.AX) Income Statement & Financial Overview
View the income breakdown for HeraMED Limited HMD.AX across both annual and quarterly reports.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $113538.00 | $120606.00 | $210287.00 | $197949.00 |
| Cost of Revenue | $35551.00 | $58902.00 | $368350.00 | $244791.00 |
| Gross Profit | $77987.00 | $61704.00 | -$158063.00 | -$46842.00 |
| Gross Profit Ratio | $0.69 | $0.51 | -$0.75 | -$0.24 |
| R&D Expenses | $455910.00 | $590263.00 | $726545.00 | $697377.00 |
| SG&A Expenses | $981598.00 | $1.69M | $1.47M | $1.40M |
| Operating Expenses | $1.50M | $2.17M | $2.19M | $2.10M |
| Total Costs & Expenses | $1.53M | $2.23M | $2.56M | $2.34M |
| Interest Income | $0.00 | -$15337.00 | $0.00 | $28278.00 |
| Interest Expense | $0.00 | $38604.00 | $33628.00 | $3373.00 |
| Depreciation & Amortization | $17307.00 | $8114.00 | $243503.00 | $204182.00 |
| EBITDA | -$1.40M | -$2.10M | -$2.08M | -$1.94M |
| EBITDA Ratio | -$12.34 | -$17.40 | -$10.02 | -$9.80 |
| Operating Income | -$1.42M | -$2.11M | -$2.35M | -$2.14M |
| Operating Income Ratio | -$12.50 | -$17.46 | -$11.17 | -$10.83 |
| Other Income/Expenses (Net) | $9145.00 | -$35966.00 | -$64827.00 | -$8109.00 |
| Income Before Tax | -$1.41M | -$2.14M | -$2.41M | -$2.15M |
| Income Before Tax Ratio | -$12.42 | -$17.76 | -$11.48 | -$10.87 |
| Income Tax Expense | $0.00 | $1.07M | $1.00 | $3.00 |
| Net Income | -$1.41M | -$2.14M | -$2.41M | -$2.15M |
| Net Income Ratio | -$12.42 | -$17.76 | -$11.48 | -$10.87 |
| EPS | -$0.002 | -$0.009 | -$0.008 | -$0.009 |
| Diluted EPS | -$0.002 | -$0.009 | -$0.008 | -$0.009 |
| Weighted Avg Shares Outstanding | $699.34M | $363.11M | $286.10M | $248.05M |
| Weighted Avg Shares Outstanding (Diluted) | $700.34M | $363.10M | $286.10M | $248.05M |
Over the last four quarters, HeraMED Limited's revenue moved from $197949.00 in Q2 2023 to $113538.00 in Q4 2024. Operating income in Q4 2024 was -$1.42M, with a strong operating margin of -1250%. Despite fluctuations in R&D and SG&A expenses, EBITDA for HeraMED Limited remained robust at -$1.40M, reflecting operational efficiency. Net income rose to -$1.41M, with an EPS of -$0.002. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan